Add BrightSurf on Google Email

Having a good breakfast reduces cardiovascular risk

Consuming 20-30% of daily energy at breakfast is associated with lower body mass index, smaller waist circumference, significantly lower triglyceride levels, and higher HDL cholesterol. A high-quality breakfast with proper balance of proteins, fats, fiber, and nutrients also contributes to reducing cardiovascular risk factors.

SourceIMIM (Hospital del Mar Medical Research Institute)·JournalThe journal of nutrition health & aging·DateDec 11, 2024

A healthy diet helps the weighty battle with chronic pain

A new study published in the journal Nutres found that adopting a healthy diet can reduce the severity of chronic pain, regardless of body weight. The research, conducted by the University of South Australia, explored associations between body fat, diet, and pain and found that higher consumption of core foods was directly associated w...

SourceUniversity of South Australia·JournalNutrition Research·TypeExperimental study·DateDec 8, 2024

Association of waist circumference with all-cause and cardiovascular mortality in diabetes from the National Health and Nutrition Examination Survey 2003–2018

A U-shaped association between waist circumference and all-cause mortality was found in women, while a J-shaped trend was observed in men with type 2 diabetes. The study suggests that optimal waist circumference thresholds for minimizing mortality risk are 107 cm for women and 89 cm for men.

CNIC scientists discover a key mechanism in fat cells that protects the body against energetic excess

Researchers identify caveolae's role in protecting adipocytes from rupture and inflammation; this discovery opens new avenues for treating metabolic diseases like obesity. The study highlights the importance of the caveolin-1 protein in maintaining cellular integrity.

SourceCentro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.)·JournalNature Communications·TypeExperimental study·DateNov 28, 2024

Alcohol use and antiobesity medication treatment

A cohort study found that nearly half of participants who consumed alcohol at baseline decreased their alcohol use after initiating anti-obesity medication treatment. The medications, such as naltrexone and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), may have properties that lead to reduced cravings for alcohol.

SourceJAMA Network·JournalJAMA Network Open·DateNov 26, 2024

Popular diabetes and obesity drugs also protect kidneys, study shows

Researchers found that GLP-1 receptor agonists reduced the risk of kidney failure by 16% and worsening of kidney function by 22%. The combined reduction in risk was 19%, showing a clear benefit on kidney protection. This study expands current knowledge about this class of drugs, highlighting their role in treating patients with chronic...

SourceGeorge Institute for Global Health·JournalThe Lancet Diabetes & Endocrinology·TypeMeta-analysis·DateNov 25, 2024

Alcohol-related deaths in the US more than double from 1999 to 2020

Researchers found that alcohol-related deaths in the US surged dramatically between 1999 and 2020, with a nearly fourfold increase in those aged 25-34. The study highlights significant gender differences and regional disparities, emphasizing the need for targeted interventions to combat the growing US alcohol mortality epidemic.

SourceFlorida Atlantic University·JournalThe American Journal of Medicine·TypeMeta-analysis·DateNov 18, 2024

Cause of the yo-yo effect deciphered

A study by ETH Zurich researchers has found that epigenetic markers in fat cells can lead to the yo-yo effect, where weight drops but returns. The researchers also found evidence of this mechanism in humans, suggesting that obesity can leave a lasting mark on gene expression.

SourceETH Zurich·JournalNature·TypeExperimental study·DateNov 18, 2024

UAB researchers cure liver disease MASH by a one-time gene therapy

Researchers from UAB have developed a gene therapy that reverses metabolic dysfunction-associated steatohepatitis (MASH) in mice, and most obese and type 2 diabetic patients could benefit from this treatment. The therapy, based on the fibroblast growth factor 21 protein, mediates long-term reversal of liver fibrosis and MASH.

SourceUniversitat Autonoma de Barcelona·JournalMolecular Therapy·TypeExperimental study·DateNov 13, 2024

What’s chubby enough for lower disability after stroke?

A recent study published in Topics in Stroke Rehabilitation found that slightly overweight stroke survivors (BMI 22.1-27.5 kg/m²) have a lower risk of sustaining disabilities compared to those with normal weight. The research suggests that a higher-than-normal BMI may be beneficial for recovering from a stroke with less disability.

SourceKobe University·JournalTopics in Stroke Rehabilitation·TypeData/statistical analysis·DateNov 5, 2024

Brighter nights and darker days could lead to an early grave

A study of over 13 million hours of data found that exposure to bright nights and dark days is associated with an increased risk of death. Those exposed to high levels of light at night had a 21–34% increased risk, while those exposed to high levels of daylight had a 17–34% reduction in their risk of death.

SourceFlinders University·JournalProceedings of the National Academy of Sciences·TypeData/statistical analysis·DateOct 30, 2024

NIH study demonstrates long-term benefits of weight-loss surgery in young people

A recent NIH study found that young people with severe obesity who underwent weight-loss surgery between ages 15 and 18 continued to see significant improvements in health outcomes, including reduced type 2 diabetes, hypertension, and abnormal cholesterol levels. The study, known as Teen LABS, suggests that bariatric surgery may offer ...

Cardiovascular risk biomarkers in inflammaging

Researchers propose a comprehensive biomarker-based approach to assess cardiovascular risk by combining markers of chronic inflammation with cardiac health indicators. This approach reveals the significant impact of aging-related inflammation, or 'inflammaging,' on heart health and opens new avenues for targeted interventions.

SourceImpact Journals LLC·JournalAging-US·TypeCommentary/editorial·DateOct 29, 2024

Terasaki Institute researchers develop promising nanoparticle-based approach to obesity treatment

Researchers at Terasaki Institute have developed simvastatin-loaded nanoparticles to target adipose tissue inflammation, promoting fat tissue browning and weight loss. The treatment effectively inhibits obesity-related inflammation, controlled white fat production, and demonstrated strong anti-inflammatory effects.

SourceTerasaki Institute for Biomedical Innovation·JournalACS Nano·TypeExperimental study·DateOct 28, 2024